<DOC>
	<DOCNO>NCT00427661</DOCNO>
	<brief_summary>Hypothesis 1 : A novel nonmyeloablative condition regimen safe efficacious produce stable donor chimerism cure severe hemoglobinopathy . Hypothesis 2 : Stable donor chimerism result amelioration cerebral vasculopathy , improved cerebral perfusion neurocognitive function . Specific Aim 1 : Study safety efficacy novel non-toxic conditioning regimen HSCT patient severe hemoglobinopathy kinetics lineage specific chimerism HSCT We test hypothesis novel nonmyeloablative condition regimen safe efficacious produce stable donor chimerism cure severe hemoglobinopathy : Specific Aim 2 : Optimize immunosuppressive regimen HSCT patient thorough understanding pharmacokinetics Busulfan ( BU ) mycophenolate mofetil ( MMF ) patient population . This involve : 1 . Determine pharmacokinetics intravenously orally administer MMF intravenous BU patient receive HSCT . 2 . Determine relationship Area curve ( AUC ) BU mean trough concentration mycophenolic acid ( MPA ) engraftment graft versus host disease ( GVHD ) . 3 . Determine relationship Area curve ( AUC ) steady state concentration BU engraftment day 30 1 year post HSCT . Specific Aim 3 : Study effect complete partial donor chimerism silent overt cerebral vasculopathy , neurocognitive functioning patient SCD undergo HSCT . We test hypothesis stable donor chimerism result improvement cerebral vasculopathy neurocognitive function . This include . 1 . Determine effect transplantation silent overt cerebral vasculopathy comparison MRA TCD 1 year HSCT pre-HSCT study . 2 . Determine effect HSCT neurocognitive function . Specific Aim 4 : To determine rate T cell immune reconstitution child sickle cell disease follow myeloablative compare nonmyeloablative stem cell transplantation , use immunophenotyping assay , CDR3 spectratyping TREC analysis , measurement T cell specific donor engraftment .</brief_summary>
	<brief_title>A Pilot Study HSCT Patients With High-risk Hemoglobinopathy Using Nonmyeloablative Preparative Regimen</brief_title>
	<detailed_description>Severe hemoglobinopathy sickle cell disease ( SCD ) Thalassemia associate considerable morbidity , organ damage premature mortality . Allogeneic hematopoietic stem cell transplantation ( HSCT ) therapy cure hemoglobinopathy . The applicability HSCT hemoglobinopathy limit paucity suitable donor , risk early regimen-related toxicity late effect . Reduction dose myelotoxic drug preparative regimen prior HSCT potential increase applicability curative option patient hemoglobinopathy . We hypothesize preparative regimen maximize host immunosuppression without myeloablation well tolerated sufficient engraftment donor hematopoietic stem cell patient severe hemoglobinopathy . The long term objective research develop novel , less toxic approach HSCT patient severe hemoglobinopathy . Specific aim : 1 . To evaluate safety efficacy novel nontoxic nonmyeloablative approach hematopoietic stem cell transplantation hemoglobinopathy . 2 . To optimize immunosuppressive regimen HSCT patient thorough understanding pharmacokinetics Busulfan ( BU ) Mycophenolic acid ( MPA ) 3 . To determine effect partial complete donor chimerism cerebral vasculopathy patient SCD . 4 . To determine rate T cell immune reconstitution child sickle cell disease follow myeloablative compare nonmyeloablative stem cell transplantation , use immunophenotyping assay , CDR3 spectratyping TREC analysis , measurement T cell specific donor engraftment . Subjects meet eligibility criterion human leukocyte antigen match , partially mismatch relate unrelated donor bone marrow umbilical cord blood receive HSCT nonmyeloablative preparative regimen consist BU , Fludarabine ( FLU ) , total lymphoid radiation Anti-Thymocyte globulin follow prophylaxis graft versus host disease cyclosporine A MMF . Patients study survival , cure hemoglobinopathy , absence severe regimen related toxicity graft versus host disease . The relationship engraftment , survival Graft versus host disease kinetics lineage specific donor chimerism area curve Mycophenolic acid Busulfan study .</detailed_description>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Hemoglobinopathies</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>Patients SCD 035 year age HLAidentical 1 HLA antigen mismatch bone marrow 2 HLA antigen mismatch umbilical cord blood ( UCB ) donor one following : Stroke , CNS hemorrhage neurologic event lasting longer 24 hour , abnormal cerebral MRI cerebral arteriogram MRI angiographic study impair neuropsychological testing , Acute chest syndrome history recurrent hospitalization exchange transfusion , Recurrent vasoocclusive pain 3 episode per year 3 year year recurrent priapism , Impaired neuropsychological function abnormal cerebral MRI scan , Stage I II sickle lung disease , Sickle nephropathy ( moderate severe proteinuria glomerular filtration rate [ GFR ] 3050 % predict normal value ) , Bilateral proliferative retinopathy major visual impairment least one eye , Osteonecrosis multiple joint document destructive change , Requirement chronic transfusion RBC alloimmunization &gt; 2 antibody long term transfusion therapy . Patients transfusion dependent Thalassemia 035 year age HLAidentical 1 HLA antigen mismatch bone marrow 2 HLA antigen mismatch UCB donor . Second Transplants Patients sickle cell disease Thalassemia fail engraft autologous recovery eligible protocol . Patients must meet criterion . If first transplant nonmyeloablative regimen , second transplant occur time . If first transplant myeloablative regimen , second transplant must &gt; 6 month first transplant . Patients one following : Karnofsky Lansky performance score &lt; 70 , Acute hepatitis evidence moderate severe portal fibrosis cirrhosis biopsy , Stage IIIIV lung disease , GFR &lt; 30 % predict normal value . Pregnant lactating female . Active serious infection whereby patient intravenous antibiotic one week prior study entry . Any patient AIDS ARC HIV seropositivity . Any patient invasive aspergillums infection within one year study entry . Psychologically incapable undergoing BMT associate strict isolation document history medical noncompliance . Patients able receive TLI due prior radiation therapy . Donor Inclusion Criteria Donor must good health base review system result physical examination . Donor must normal hemoglobin , white count , platelet count PTT . Female donor childbearing potential must negative pregnancy test . Donor Exclusion Criteria Donor active infection ( include HIV , hepatitis ) . Donor lactate female . Donor Selection In case one donor meet eligibility criterion , donor selection guide following consideration : HLA A , B , DRB1 identical sibling donor preferable unrelated donor Homozygous normal donor preferable heterozygote ( carrier ) ABOcompatible donor preferable ABOincompatible donor Younger donor preferable old Cytomegalovirus seronegative donor preferable CMV seropositive donor , patient CMV negative</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Sickle Cell Disease</keyword>
	<keyword>Thalassemia</keyword>
	<keyword>Hemoglobinopathies</keyword>
</DOC>